HONG, KONG/LONDON – Takeda Pharmaceutical Co. is nearing the sale of a portfolio of assets in the Middle East, Africa and Russia to separate buyout firms that could help the drugmaker raise about $1 billion to reduce debt, according to people familiar with the matter.
The company is in advanced talks to sell over-the-counter and prescription-drug assets in Russia to Stada Arzneimittel AG, the German pharmaceutical firm owned by Cinven and Bain Capital, the people said, asking not to be identified because the deliberations are private.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.